Technical Analysis for KPTI - Karyopharm Therapeutics Inc.

Grade Last Price % Change Price Change
D 0.78 0.26% 0.00
KPTI closed up 0.26 percent on Wednesday, November 20, 2024, on 44 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
NR7-2 Range Contraction 0.00%
Oversold Stochastic Weakness 0.00%
New Downtrend Bearish 0.26%
NR7 Range Contraction 0.26%
Doji - Bullish? Reversal 0.26%
Down 3 Days in a Row Weakness 0.26%
Down 4 Days in a Row Weakness 0.26%
Down 5 Days in a Row Weakness 0.26%
Gapped Down Weakness 0.26%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 18 hours ago
Rose Above Previous Day's High about 20 hours ago
Down 2 % about 22 hours ago
Down 1% about 22 hours ago
Lower Bollinger Band Support about 22 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Karyopharm Therapeutics Inc. Description

Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. The company's lead drug candidate includes Selinexor, an oral selective inhibitors of nuclear export (SINE) compound that specifically blocks XPO1 cargo binding is in Phase I clinical trials in patients with heavily pretreated relapsed and/or refractory hematological and solid tumor malignancies. Its other drug candidates comprise KPT-350 and related SINE compounds; PAK4 inhibitors; and Verdinexor, a SINE compound that is in Phase IIb clinical trials in pet dogs with newly-diagnosed or first relapse after chemotherapy lymphomas. The company was founded in 2008 and is based in Natick, Massachusetts.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Medicine Cancer Pharmaceutical Disease Oncology Treatment Of Cancer Chemotherapy Lymphoma Occupational Safety And Health Dog Stage Pharmaceutical Antibody Drug Conjugate

Is KPTI a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 1.95
52 Week Low 0.6174
Average Volume 835,609
200-Day Moving Average 1.02
50-Day Moving Average 0.83
20-Day Moving Average 0.86
10-Day Moving Average 0.84
Average True Range 0.07
RSI (14) 40.83
ADX 29.84
+DI 16.34
-DI 16.77
Chandelier Exit (Long, 3 ATRs) 0.93
Chandelier Exit (Short, 3 ATRs) 0.95
Upper Bollinger Bands 0.97
Lower Bollinger Band 0.75
Percent B (%b) 0.1
BandWidth 24.98
MACD Line -0.01
MACD Signal Line 0.00
MACD Histogram -0.0164
Fundamentals Value
Market Cap 88.76 Million
Num Shares 115 Million
EPS -1.31
Price-to-Earnings (P/E) Ratio -0.59
Price-to-Sales 1.19
Price-to-Book 12.05
PEG Ratio -0.15
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.83
Resistance 3 (R3) 0.83 0.81 0.82
Resistance 2 (R2) 0.81 0.80 0.81 0.82
Resistance 1 (R1) 0.79 0.79 0.80 0.79 0.81
Pivot Point 0.78 0.78 0.78 0.78 0.78
Support 1 (S1) 0.76 0.76 0.77 0.76 0.74
Support 2 (S2) 0.74 0.75 0.74 0.73
Support 3 (S3) 0.72 0.74 0.73
Support 4 (S4) 0.72